Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1267 - Prognostic factors for response and outcome in high body mass index DLBCL patients: a single center retrospective study from South India


19 Dec 2015


Poster presentation 1


Ranga Raman Ganta


Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526


R.R. Ganta, S. Nasaka, L.V. Gandhi, L.S. Maddali, D. Raghunadha Rao

Author affiliations

  • Medical Oncology, Nizam's Institute of Medical Sciences, 500082 - Hyderabad/IN


Abstract 1267


High body mass index (BMI) is an important risk factor influencing the outcome of several types of cancer including lymphomas which is most likely due to altered pharmacodynamics and pharmacokinetics of therapeutic drugs. DLBCL patients are heterogeneous and their outcome depends on the interplay of several prognostic factors. Therefore, it remains unclear which factors have greater impact on response and outcome. We aimed to study various prognostic factors among high BMI DLBCL population.


This is a retrospective single-center analysis of DLBCL patients with high BMI (≥25.0 kg/m2) and was treated with standard chemotherapy +/- Rituximab as first-line therapy between 2002 and 2010. They were analyzed for the factors which influence outcome like age, sex, performance status, B symptoms, stage, bulkiness status, LDH, IPI score, marrow involvement, extranodal involvement. The prognostic factors were compared using multivariate analysis in achievement of complete remission (CR) at the end of treatment and 5 year overall survival (OS).


A total of 88 (19%) among 449 DLBCL patients had high BMI patients, with median age of 46 years (range 14-80) and male preponderance (M:F = 1.26:1). The correlation of achievement of CR with the variables is as follows: age ≤ 60 vs > 60 (p = 0.9), male vs female (p = 0.4), performance status < 2 vs ≥2 (p = 0.02), B symptoms presence vs absence (p = 0.9), early stage vs advanced (p = 0.04), presence vs absence of bulky disease (p = 0.76), normal vs elevated LDH (p = 0.71), low vs intermediate vs high IPI score (p = 0.2), marrow involvement vs absence (p = 0.03), extranodal involvement vs absence (p = 0.41). The correlation of 5 year OS with the variables is as follows: age ≤ 60 vs > 60 (p = 0.7), male vs female (p = 0.9), performance status < 2 vs ≥2 (p = 0.03), B symptoms presence vs absence (p = 0.36), early stage vs advanced (p = 0.01), presence vs absence of bulky disease (p = 0.74), normal vs elevated LDH (p = 1.0), low vs intermediate vs high IPI score (p = 0.4), marrow involvement vs absence (p = 0.01), extranodal involvement vs absence (p = 0.72).


The response and outcome of high BMI DLBCL patients is significantly correlated with the performance status, stage and marrow involvement.

Clinical trial identification



All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings